FACEMIL®
Apremilast 10 mg, 20 mg y 30 mg (Initiation Kit). Coated tablets.
Apremilast 30 mg (Maintenance Kit). Coated tablets.
Pharmaceutical form
Coated tablets.
Therapeutical action
Selective immunosuppressant
Indications
Psoriatic Arthritis:
FACEMIL® is indicated for the treatment of active Psoriatic Arthritis (PsA).
Psoriasis:
FACEMIL® is indicated for the treatment of moderate to severe chronic plaque Psoriasis in adult patients who are candidates for phototherapy or systemic therapy.
Dose and Administration
After an initial titration schedule, the recommended dose of FACEMIL® is 30 mg twice daily taken orally, morning and evening, approximately 12 hours apart, with no food restrictions. For further details, see information in the product leaflet.
How supplied
FACEMIL®/ APREMILAST 10 mg, 20 mg y 30 mg (Initiation Kit): package containing 4 coated tables 10 mg + 4 coated tablets 20 mg + 19 coated tables 30 mg.
Storage